ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 130 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $43,445,336 | +0.1% | 2,758,434 | 0.0% | 0.83% | +3.1% |
| Q3 2022 | $43,418,000 | +33.7% | 2,758,434 | +18.6% | 0.81% | +37.1% |
| Q2 2022 | $32,464,000 | +19.2% | 2,325,500 | +47.2% | 0.59% | +33.0% |
| Q1 2022 | $27,237,000 | +90.0% | 1,579,900 | +60.2% | 0.44% | +140.2% |
| Q4 2021 | $14,335,000 | +22.2% | 985,900 | +51.3% | 0.18% | +42.6% |
| Q3 2021 | $11,732,000 | +84.6% | 651,783 | +80.1% | 0.13% | +101.6% |
| Q2 2021 | $6,357,000 | – | 362,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |